JonesTrading initiated coverage on Ocuphire Pharma with a new price target
$OCUP
Biotechnology: Pharmaceutical Preparations
Health Care
JonesTrading initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $20.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2021 | $26.00 | Buy | HC Wainwright & Co. |
Submission status for OCUPHIRE PHARMA INC's drug RYZUMVI (ORIG-1) with active ingredient PHENTOLAMINE has changed to 'Approval' on 09/25/2023. Application Category: NDA, Application Number: 217064, Application Classification: Type 3 - New Dosage Form